REPORT. INVESTIGATOR. R. Vanhoof 1, WIV/ISP Pasteurinstituut - Brussel, Eenheid Antibiotica-Onderzoek, Engelandstraat 642, B-1180 Brussel.
|
|
- Horatio Sanders
- 6 years ago
- Views:
Transcription
1 REPORT. In vitro study to investigate the antimicrobial activity of various antibiotics against noninvasive clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 7-8 (SP8). INVESTIGATOR. R. Vanhoof, WIV/ISP Pasteurinstituut - Brussel, Eenheid Antibiotica-Onderzoek, Engelandstraat 6, B-8 Brussel. «No part of this report - including graphs, figures, tables may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing form from an authorized person representing the Scientific Institute of Public Health» The nd of September 8
2 INTRODUCTION. S. pneumoniae, with its high degree of morbidity and its considerable rate of mortality, is one of the most commonly identified pathogens both in community and hospital acquired infections. In 967, the first penicillin-insusceptible S. pneumoniae strain was reported from Australia and since then antibiotic resistance in this micro-organism became a problem of paramount importance. High rates of insusceptibility to penicillin and other related and unrelated compounds have been reported world-wide. Over the years, penicillin insusceptible isolates became more and more concomitantly resistant to other classes of antimicrobials. This can be attributed to the de novo acquisition of new genetic material and the clonal spread of resistant isolates. In Belgium, the first two penicillin resistant isolates were reported by Vanhoof et al in 985. The situation had been evolving less spectacular but since the beginning of the nineties both the Antibiotic research Unit of the Institute Pasteur of Brussels and the National Reference Centre have been reporting a slow but steadily increase in penicillin insusceptibility in clinical isolates. In the former surveillance studies, we reported a level of penicillin insusceptibility of.5,.3, 6.,., 5.,.7, 5.,.8 and. for winter 995, 997, 999,, 3,, 5, 6 and 7 respectively. The epidemiology of antibiotic resistance can be influenced by various parameters and geographic differences, even on a regional scale, have been reported. These findings underline the necessity for continuous national and international surveillance of resistance. Therefore we organized this th collaborative surveillance study, to monitor possible changes in antibiotic resistance in non-invasive clinical isolates of S. pneumoniae collected by 5 participating centres. MATERIAL AND METHODS. This study was conducted in collaboration with 5 selected clinical centres in Belgium. The aim of this eight annual surveillance study was to obtain information on the level and evolution of antibiotic resistance in Belgian isolates of S. pneumoniae. The isolates of Streptococcus pneumoniae prospectively collected were obtained from the following centres: Hôpital de la Citadelle, Liège. (Dr. M. Carpentier), Laboratoire Cebiodi, Bruxelles (Dr. B. Mulongo), Clinique Universitaire de Mont-Godinne, Yvoir (Dr. Y. Glupczynski), Clinique St. Joseph, Arlon (Dr. P. Goffinet), C.H.U. André Vésale, Montignies-le-Tilleul (Dr. D. Govaerts), Hôpital Princesse Paola, Marche-en-Famenne (Dr. Ph. Lefèvre), Medisch
3 Centrum Huisartsen, Leuven (Apoth. M. Lontie), Virga-Jesseziekenhuis, Hasselt (Dr. R.Cartuyvels), Hôpital de Jolimont, Haine-St.-Paul (Dr. F. Meunier), CHR Hôpital de Warquignies, Boussu (Dr. I. Philippart), H. Hartziekenhuis, Roeselare (Dr. I. Surmont), A.Z. Stuivenberg, Antwerpen ( Dr. K. Camps), A.Z. St. Jan, Brugge (Dr. B. Gordts), A.Z. Jan Palfijn, Gent (Dr. L. Ide) and Imeldaziekenhuis, Bonheiden (Dr. J. Frans). The following antibiotics were tested in the study and were provided as laboratory preparations with known potency: clavulanic acid, ceftazidime (GlaxoSmithKline), cefepime (Bristol Myers Squibb), cefotaxime, levofloxacin, ofloxacin and telithromycin (Sanofi Aventis), ciprofloxacin and moxifloxacin (Bayer), azithromycin (Pfizer). Amoxicillin, ampicillin, cefaclor, cefuroxime, clindamycin, erythromycin, penicillin G and tetracycline were obtained from a commercial source (Sigma). Imipenem was obtained from Fisher Scientific, USA. Amoxicillin/clavulanic acid was tested in a : ratio. All antibiotics were tested for 6 serial twofold dilutions (. 3 µg/ml). The Minimal Inhibitory Concentrations (MICs) were determined by broth microdilution as recommended by the CLSI. All isolates underwent a slide agglutination (Slidex pneumo Kit TM, BioMérieux) and an Optochine test (OPTO-F, BioMérieux) before MIC testing. All the isolates were also tested for the LytA gene by PCR. S. pneumoniae ATCC 969, S. pneumoniae TPN88 (internal control isolate) and Staphylococcus aureus NCTC 56 (ß-lactamase positive to validate the clavulanate component of amoxicillin/clavulanate) were included as quality control organisms in each series. Interpretation of the results was based on breakpoints provided by the CLSI. Levels of susceptibility to ampicillin were determined by the penicillin breakpoints. For ciprofloxacin, we used breakpoints of one dilution lower than those of levofloxacin as is generally the case for other types of micro-organisms. The penicillin insusceptible isolates were typed by the National Reference Centre by using the Quellung reaction with sera from the Staten Serum institute (Copenhagen, Denmark). The Chi-square test, with or without Yates correction, for two independent samples was used for the statistical evaluation of the results. The level of significance was set at.5. RESULTS. In total 8 documented isolates of S. pneumoniae were included in the study for further analysis. Seventeen point four percent (78/8) of the isolates were from children (age 5 years) with 66/78 or 8.6 from children under 5 years of age, while 8.6 (37/8) were from adults with 38/37 or 6.3 from adults with age 6 years. Age showed a 3
4 bimodal distribution with a first peak between and 5 years (.7 ) and a second peak between 6 and 8 year (5. ). The mean age of the study population was 53. years. The mean age per collection centre varied from 38. years (Medisch Centrum Huisartsen, Leuven) to 73.7 (Hôpital Princesse Paola, Marche-en-Famenne). Isolates from sputum represented 79.9 (358/8) of the specimens, 5. (69/8) were from nasal swab,.5 (/8) from throat,.8 (8/8) from sinus and. (/8) from respiratory pus. Overall, 79.9 the isolates were from lower respiratory tract (LRT) specimens and. from upper respiratory tract (URT). Isolates from sputum were significantly more present in patients of the age group 6 years (96. 9/38) when compared to the other age groups: -5 years (. ; 8/66; P<.), 6-5 years (58.3 ; 7/; P <.) and 6-59 years (86. ; /3;.> P >.). Isolates from sputum were also more present in the age group 6-59 years (86. ; /3) than in the age groups -5 years (. ; 8/66; P<.) and 6-5 years (58.3 ; 7/;.5 > P >.). Overall, this means that Sputum samples were significantly more present in adults than in children (95.8 versus.; P <.). Isolates from upper respiratory tract origin were significantly more present in children than in adults (7. versus 3. ; P <.). This was especially due to the age group -5 years in which 87.9 of the samples were from URT. Isolates from hospitalised patients represented 6.7 (8/8) of the isolates while 35.3 (58/8) were from ambulatory patients and. (9/8) from long care facility patients. Sixty four point one percent (87/8) of the isolates were from male patients. Isolates from the Northern part of the country represented 6.7 (9/8) while 5.5 (/8) and 7.8 (35/8) of the isolates came from patients from the Southern part and Brussels respectively. The highest intrinsic activity on a weight basis was found for imipenem (MIC 5, or MIC for 5 of the isolates tested, of. µg/ml) followed by amoxicillin, amoxicillin/clavulanic acid, and telithromycin (MIC 5.8 µg/ml), penicillin G, ampicillin cefotaxim, ceftazidime, cefepime, (MIC 5.5 µg/ml), cefuroxime (MIC 5,3 µg/ml), moxifloxacin, erythromycin, azithromycin (MIC 5.6 µg/ml), tetracycline (MIC 5. µg/ml), cefaclor, clindamycin, (MIC 5.5 µg/ml), levofloxacin (MIC 5.5 µg/ml), ciprofloxacin and ofloxacin (MIC 5. µg/ml) (Table ). Telithromycin, amoxicillin, amoxicillin/clavulanic acid, moxifloxacin, levofloxacin, cefotaxime, ceftazidime and cefepime were the compounds with the highest level of susceptibility (,,, 99.6, 99.3, 98, 98, and 98 resp.) followed by imipenem, ciproflocacin, ofloxacin, cefuroximeaxetil and cefuroxime (97.5, 9.9, 9.9, 9.3 and 9.8 resp.).
5 5
6 The lowest degrees of susceptibilitiy were found for erythromycin, azithromcycin, clindamycin and tetracycline (7.3, 7.3, 73.7 and 78. respectively.) (Table ). TABLE : SUSCEPTIBILITY RATES FOLLOWING CLSI CRITERIA OF 8 NON- INVASIVE ISOLATES OF S. pneumoniae. (SP8) Antibiotic Susceptibility Rates (in ) Susceptible Intermediate Resistant Penicillin Ampicillin Amoxicillin Amoxicillin/clavulanate Cefaclor Cefuroxime Cefuroxime-axetil Cefotaxime 98.. Ceftazidime 98.. Cefepime 98.. Imipenem Ciprofloxacin Levofloxacin Moxifloxacin Ofloxacin Erythromycin Azithromycin Telithromycin Clindamycin Tetracycline See comment Text Cefuroxime-axetil: oral form of Cefuroxime Decreased susceptibility (I+R) to penicillin was.6 [7.6 intermediate (I =. - µg/ml) and. high-level (R µg/ml)], ampicillin. [7. I (=. - µg/ml) and. R ( µg/ml)], amoxicillin ± clavulanic acid [I = µg/ml and R 8 µg/ml], cefaclor.3 [.7 I (= µg/ml) and 9.6 R ( µg/ml)], cefuroxime 9. [.5 I (= µg/ml) and R ( µg/ml)], cefuroxime-axetil 8.7 [.9 I (= µg/ml) and 7.8 R ( µg/ml)], cefotaxime, ceftazidime and cefepime. [. I (= µg/ml) and (R µg/ml)], imipenem.5 [.5 I (=.5.5 µg/ml) and R ( µg/ml)], ciprofloxacin 5. [.7 I (= µg/ml) and. R ( µg/ml)], levofloxacin.7 [. I (= µg/ml) and.5 R ( 8 µg/ml)], moxifloxacin. [. I = µg/ml and. R = µg/ml)], ofloxacin 5. [.7 I (= µg/ml) and. R ( 8 µg/ml)], erythromycin 9.7 [.5 I (=.5 µg/ml) and 9. R ( µg/ml)], azithromycin 9.7 [.9 I (= µg/ml) and 8.8 R ( µg/ml)], telithromycin [I = µg/ml and R 6
7 µg/ml)], clindamycin 6.3 [.9 I (=.5 µg/ml) and 5. R ( µg/ml)] and tetracycline.9 [5. I (= µg/ml) and 6.5 R ( 8 µg/ml)] (Table ). In general, isolates showing resistance to an antibiotic (IR-isolates) were more present in children (36/78, 6. ) than in adults (3/37; 35.7 ) though the difference was not significant. Furthermore, there was no significant difference between the different age groups as far as the presence of IR-isolates is concerned. Resistance to erythromycin was significantly higher in children (.3 ; 33/78) than in adults (7.3 ; /37) (.>P>.). Resistance in the age group -5 year (3.9 ; 9/66) was also significantly higher than in the age groups 6-59 years (.; 3/3,.>P>.) and 6 year (9.; 69/38;.5>P>.). For Tetracycline there was a significant difference between the age group -5 year (3.8; /66) and 6-59 year (8.; /3) (.5>P>.). No further significant differences were found in the various age groups. Table 3 : of isolates in different age groups with resistance to age Pen Cip Ery Tet IR S Children Adults total Fig. : Resistance Rates: Children versus Adults (8) P C E*** T R (*Significant difference) Child Adult 7
8 Table : Resistance rates () in URT and LRT isolates (8) Pen Cip Ery Tet IR S URT LRT TOT Fig. : Resistance rates in URT and LRT (8) URT LRT 5 P C E T IR Isolates showing antibiotic resistance were more prevalent in URT (. ) than in LRT (36.9 ) though the difference was statistically not significant. No significant differences were found for penicillin, ciprofloxacin, erythromycin and tetracycline. Fig.3: Resistance rates by region (8) P* C E T IR North South Bruss In general, the presence of isolates with decreased antibiotic susceptibility revealed to be comparable in the three different regions: Brussels (. ), the Southern part (38.7 ) and the Northern part (35.9 ). The only significant difference was found for penicillin between Brussels (.9, 8/35) and the Northern part (8. ; 7/9) (.>P>.). No other significant differences were found for the different antimicrobials. 8
9 Table 5 : Resistance rates () following gender and type of isolate Pen Cip Ery Tet IR S Gender Male Female Type AMB HOSP LCF AMB:Ambulatory; HOS:Hospitalized; LCF:Long Care Facility Tetracycline resistance was significantly higher in males (5. ; 73/87) than in females (5.5 ; 6/6) (Table 5). As far as the admission type (ambulatory, hospitalized) concerned, no significant differences were found (Table 5). The most common resistance phenotypes (Table 6) were insusceptibility to Erythromycin-Tetracycline (.7 ), isolated insusceptibility to Erythromycin (7. ) followed by insusceptibility to Penicillin-Erythromycin-Tetracycline (5.8 ). TABLE 6 : DISTRIBUTION OF THE PENICILLIN-CIPROFLOXACIN- ERYTHROMYCIN-TETRACYCLINE SUSCEPTIBILITY PHENOTYPES (8). Penicillin-Erythromycin-Tetracycline-Ciprofloxacin phenotype Number () Susceptible 8 (6.5) Ery-Tet 57 (.7) Ery 33 (7.) Pen-Ery-Tet 6 (5.8) Cip 5 (3.) Pen (.) Pen-Ery (.) Tet 9 (.) Pen-Cip-Ery-Tet (.9) Cip-Ery-Tet (.5) Pen-Cip (.) Pen-Cip-Ery (.) Insusceptibility to one compound was present in 5. of the isolates. Two-, three- and fourfold resistance was found in 5., 6.5 and.9 respectively of the isolates. 9
10 Fig.: Distribution of Resistance Phenotypes 6,5,9 5, 5, 6,5 S AB AB 3AB AB MICs of all ß-lactams rose with those of penicillin. Overall, penicillin, ampicillin, Cefotaxime, ceftazidime and cefepime were equally active against the penicillin insusceptible isolates. Imipenem was generally three doubling dilutions more potent on a weight basis, while amoxicillin, amoxicillin/clavulanate were generally one doubling dilution more potent. Cefuroxime and Cefuroxime-axetil were two dilutions less active while cefaclor was 6 dilutions less active. Cross-resistance between penicillin and the other ß-lactams was not complete. The results indicate that of the penicillin-insusceptible isolates remained susceptible to amoxicillin ± clavulanate while 8.7 of the penicillin-insusceptible isolates remained susceptible to cefotaxime, ceftazidime, cefepime and 78.8 to imipenem (Table 7).
11 TABLE 7 : MIC VALUES OF ß-LACTAMS FOR VARIOUS PENICILLIN SUSCEPTIBILITY CATEGORIES (8). ß-Lactam PEN S (n = 396) PEN I/R (n = 5) MIC5 MIC9 MIC5 MIC9 S Penicillin Ampicillin Amoxicillin Amoxicillin/Clavulanate Cefaclor Cefuroxime Cefuroxime-axetil Cefotaxime Ceftazidime Cefepime Imipenem Oral form of cefuroxime The most important capsular types in penicillin-insusceptible isolates were capsular types 9 (5. ), (9.3 ), 3 (5.) 5 (3.5) 6 (9.6) and 9 (7.7 ).Other types were capsular type 7,, 9, 3 and 35 (each.9 ). Comparison with former surveys. Resistance rates. Table 8 summarizes the resistance rates for the different antimicrobial compound tested in the various surveillance studies conducted between 995 and 8. The graphic representations of the evolution for the most important classes of compounds are given in Fig. 5, 6 and 7. Penicillin G peaked in (.) and there is a clear downwards tendency in resistance to notice after with an actual resistance rate of.6. This resistance rate is in fact lower than the rate found in 995 (.5) at the start of the surveillance programme. The other beta-lactams followed this evolution though some minor shifts in time can be found. Ciprofloxacin peaked in 999 (5.) and decreased systematically since then. Levofloxacin had its peak of resistance in 3 (3.3) and followed the downward tendency of Ciprofloxacin. The resistance rate of Moxifloxacin remained low between and.6 (3). Rates for Macrolides (MLS) and Tetracycline ware fluctuating in time.
12 Table 8 : Non-susceptibility rates (IR) obtained in the various surveys PEN AMP AMX AMC CFC CRX CRXa CTX CTZ NT NT NT NT NT CPM NT NT NT NT NT IMI CIP LEV MOX OFL ERY AZI NT NT NT TEL NT NT NT NT.. CLI NT NT TET Fig. 5: Evolution of Resistance in Beta-Lactams PEN AMX CRX CTX IMI Fig 6: Evolution of Resistance in Fluoroquinolones CIP LEV MOX
13 Fig, 7: Evolution of Resistance in MLS and TET ERY TEL TET Interestingly, the absolute number of isolates showing high level resistance (MIC µg/ml) to Penicillin G decreased between and 7 (6.,.9,.8 and.7), though a slight increase in percentage was noted in 8 (.). In any case, the intermediate isolates (. µg/ml to. µg/ml) outnumbered the isolates with high level resistance to Penicillin G in the period -8 (Fig.8). In 997, 999 and 3, the number of high level isolates was more important than the intermediate isolates (6.7 vs 5.5; 9.7 vs 5. and 8. vs. 6.7 respectively). In 995 and, the numbers in both groups were nearly comparable. This indicates that there exists a general trend in lowering the number of isolates with high level resistance to Penicillin G. However, attention should be paid to the slight increase in 8. 3
14 Fig. 8: of isolates with I and R to Pen ,7 8, 6, 5,7 6,7 9,7, 6, 5,5 8, 6,7 5,,9,8,7,3 9, 7, R I As can been seen in Fig. 9, resistance to Ciprofloxacin and other fluoroquinolones is mainly due to the presence of isolates showing intermediate resistance. The only exception was 7. In this year, a slight predominance of high level isolates was seen though the difference between the two groups was very discrete. Fig. 9: of isolates with I and R to CIP 6 3,,8, 8 6 3,6,3,5 3,,3,7 7,7 6,6 9,5, 8, 6,6 6,,7, R I
15 Evolution of MIC distributions. Fig. : MIC distribution of PEN ,,,3,6,,5, Fig. shows clearly a bimodal distribution of the MIC for Penicillin G. This was also the case for the other beta-lactam antibiotics. This bimodal distribution was found in every survey. The bimodal character indicates that there exists a distinct modus for a susceptible population and another modus for the non-susceptible population. The Modus of the population was.5 µg/ml as it was the case since. This indicates that the population did not shift to higher MIC values. Fig. : Evolution of MIC5 in PEN-S and PEN-non S isolates PEN-S PEN-I PEN-R 5
16 Fig. shows the evolution of the MIC5 (expressed in µg/ml) values in Penicillin susceptible and Penicillin non-susceptible isolates collected during the various surveillance studies. The MIC5 can be considered as the indicator for intrinsic activity. The lower the value, the more active the compound is on a given population. A population becomes less sensitive to a certain compound when the MIC5 value shifts to the right side of the curve (i.e. the higher values). As it can be seen from this figure, the MIC5 increased importantly from 995 (.8 µg/ml) to 3 (.3 µg/ml), indicating that in this period the penicillin susceptible population became less susceptible. From, the MIC5 was positioned at a lower value i.e..5 µg/ml (with the exception of.8 µg/ml in 7). The MIC5 value for the non-susceptible did not vary significantly during the years. This means that the shift of the modus in the total population is due to changes in the susceptible population rather than to changes in the non-susceptible strains. Fig. : MIC distribution of CIP ,3,6,,5, Fig,3: MIC Distribution of LEV ,3,6,,5,
17 Fig,: MIC distribution of MOX ,,,3,6,,5,5 7 8 Fig,5: MIC distribution of OFL ,,5, Figures to 5 show the MIC distributions of Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MOX) and Ofloxacin (OFL). As can been seen from these figures, the modus of the populations in the different years and for the different compounds did not fluctuate significantly. Furthermore, these compounds did not have a bimodal distribution. There distributions remained very Gaussian during the years. From figures 6, 7 and 8 it can be seen that for all the fluoroquinolones (Ofloxacine included but not shown as it is completely comparable to ciprofloxacin) the MIC5 value in both the susceptible and non-susceptible population did not shift in the various surveys. This indicates that the intrinsic activity of these compounds remained fairly stable during he period
18 Fig. 6: Evolution of MIC5 in CIP-S and CIP-non S isolates CIP-S CIP-I CIP-R Fig. 7: Evolution of MIC5 in LEV-S and LEV-non S isolates LEV-S LEV-I LEV-R 8
19 FIG. 8: Evolution of MIC5 in MOX-S and MOX-non S isolates MOX-S MOX-I MOX-R Comparison of Fluoroquinolone resistance rates following CLSI and EUCAST. Table 9: CLSI and EUCAST breakpoints for FQ CLSI EUCAST S I R S I R CIP,5,5- LEV 8 MOX,5 OFL 8,5,5-8 Table 9 compares the breakpoints of CLSI with those proposed by EUCAST. For EUCAST the wild type S.pneumoniae is not considered susceptible to Ciprofloxacin or Ofloxacin is therefore categorized as intermediate. The breakpoints for Levofloxacin relate to high dose therapy. Table and figures 9- show that the resistance rates for Levofloxacin and Moxafloxacin are very comparable if not identical with the two sets of breakpoints. On te other hand, there is an important difference for Ciprofloxacin and Ofloxacin (not shown inn figures), as the result of the categorization of the isolates as wild type for these two compounds. 9
20 Table : of non-susceptibiliy for Fluoroquinolones following CLSI and EUCAST breakpoints CLSI EUC CLSI EUC CLSI EUC CLSI EUC CLSI EUC CLSI EUC CIP 3,8 96, 9 96,7 7, 96, 8,6 98, 3,9 98,3 5, 99,3 LEV 3,3 3,3,8,8,6,6,5,5,9,7, MOX,5,5,,,,,,,7,5, OFL 3,5 99,5 9 98,8 7, 97,3 8, 99,5 3,6 99,5 5, 99,8 Fig. 9: CIP resistance rates following CLSI and EUCAST 96, 96,7 96, 98, 98,3 99,3 8 6 CLSI EUCAST 3,8 9 7, 8,6 3,9 5, Fig.: LEV resistance rates following CLSI and EUCAST 3,5 3,5 3,3,3,8,8,5,5,7,6,6,5,5,9, CLSI EUCAST Fig.: MO X resistance rates following CLSI and EUCAST,7,7,6,5,5,5,5,,3,,,,,,,, CLSI EUCAST,
INVESTIGATOR. R. Vanhoof 1, Engelandstraat 642, B-1180 Brussel.
REPORT. In vitro study to investigate the antimicrobial activity of various antibiotics against noninvasive clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 2-3 (SP3). INVESTIGATOR.
More informationANNUAL REPORT. Antimicrobial activity of various antibiotics against non-invasive clinical isolates of Streptococcus pneumoniae
21 ANNUAL REPORT In vitro study to investigate the antimicrobial activity of various antibiotics against non-invasive clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 29-21
More informationREPORT. Antimicrobial activity of various antibiotics against non-invasive clinical isolates of Streptococcus pneumoniae
212 REPORT In vitro study to investigate the antimicrobial activity of various antibiotics against non-invasive clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 211-212
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationStreptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More information1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS
PROTOCOL For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 1 INTRODUCTION... 1 2 OBJECTIVES...
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationMain objectives of the EURL EQAS s
EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationand Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA
Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationPROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains
PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationANTIMICROBIAL RESISTANCE IN KENYA; What Surveillance tells us
ANTIMICROBIAL RESISTANCE IN KENYA; What Surveillance tells us Sam Kariuki Kenya Medical Research Institute Introduction Although no systematic national surveillance is in place, few sentinel studies indicate
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationSMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationTrends en voorkomen van resistenties bij Salmonella, Campylobacter en E. coli geïsoleerd uit de voeding
Trends en voorkomen van resistenties bij Salmonella, Campylobacter en E. coli geïsoleerd uit de voeding Cristina Garcia-Graells, Nadine Botteldoorn, Katelijne Dierick NRL AMR Food Pathogens - AMCRA 30/06/2017
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationCiprofloxacin and azithromycin resistance of Campylobacter spp isolated from international travellers,
Ciprofloxacin and azithromycin resistance of Campylobacter spp isolated from international travellers, 2008-2014 Niki van Waterschoot a, Annelies Post b, Emmanuel Bottieau b, Erika Vlieghe b, Marjan Van
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationThere are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationMRSA surveillance 2014: Poultry
Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationPopulation distributions of minimum inhibitory concentration increasing accuracy and utility
Journal of Applied Microbiology ISSN 364-572 ORIGINAL ARTICLE Population distributions of minimum inhibitory concentration increasing accuracy and utility R 2 -Scientific, Sharnbrook, Bedfordshire, UK
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationAntimicrobial susceptibility of Salmonella, 2016
susceptibility of Salmonella, 06 Hospital and community laboratories are requested to refer all Salmonella isolated from human salmonellosis cases to ESR for serotyping and the laboratory-based surveillance
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationSurveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens
Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens Dr Pat Mitchell R & I Manager Production Stewardship APL CDC Conference, Melbourne June 2017 Dr Kylie Hewson
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationReceived 17 December 2003; accepted 22 December 2003
Journal of Antimicrobial Chemotherapy (2004) 53, 609 615 DOI: 10.1093/jac/dkh130 Advance Access publication 3 March 2004 In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines,
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix O 3 December 2014 Final version Commissioned
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationTaiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationCommunity-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP) Infectious Diseases Advisory Board 14/01/2000 - Woluwé St Lambert Colloquium Longartsen - 11/02/2000 Dr Yvan Valcke Belgian guidelines on the initial diagnostic and therapeutic
More informationREPORT OF THE NATIONAL EPIDEMIOLOGIC SURVEY OF ENTEROBACTER AEROGENES IN BELGIAN HOSPITALS IN
REPORT OF THE NATIONAL EPIDEMIOLOGIC SURVEY OF ENTEROBACTER AEROGENES IN BELGIAN HOSPITALS IN 1996-98. Y. De Gheldre 1, M.J. Struele 1, C. Nonhoff 1, N. Maes 1, P. De Mol 2, H. Chetoui 2, Y. Glupczyki
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntimicrobial Resistance Trends in the Province of British Columbia
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More informationAntimicrobial susceptibility testing of Campylobacter jejuni and C. coli. CRL Training course in AST Copenhagen, Denmark 23-27th Feb.
Antimicrobial susceptibility testing of Campylobacter jejuni and C. coli CRL Training course in AST Copenhagen, Denmark 23-27th Feb. 2009 Methodologies E-test by AB-biodisk A dilution test based on the
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationREVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER.
REVOLUTIONARY. Are recurrent bacterial infections a frustration in your practice? WE HAVE FOUND THE ANSWER. MMinimum inimizing BBiofilm EEradication C oncentration Concentration www.becscreen.com WHY BIOFILM
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationPalpasa Kansakar, Geeta Shakya, Nisha Rijal, Basudha Shrestha
In-vitro resistance of Salmonella Typhi and Paratyphi A raises concern on the use of older fluroquinolones in the empiric treatment of enteric fever in Nepal Palpasa Kansakar, Geeta Shakya, Nisha Rijal,
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More information